Table 1.
Patient demographics and characteristics at baseline for all treated patients
| All treated patients (N=52) | |
| Age, median (range), years | 64 (23–86) |
| Male, n (%) | 36 (69.2) |
| IMDC risk group, n (%) | |
| Favorable | 9 (17.3) |
| Intermediate | 27 (51.9) |
| Poor | 16 (30.8) |
| Karnofsky performance score, n (%) | |
| 100 | 15 (28.8) |
| 90 | 25 (48.1) |
| 80 | 9 (17.3) |
| 70 | 3 (5.8) |
| Prior nephrectomy, n (%) | 35 (67.3) |
| Prior radiotherapy, n (%) | 4 (7.7) |
| Histological subtype, n (%) | |
| Non-clear cell | 52 (100) |
| Unclassified | 22 (42.3) |
| Papillary | 18 (34.6) |
| Chromophobe | 7 (13.5) |
| Translocation-associated | 2 (3.8) |
| Collecting duct | 2 (3.8) |
| Renal medullary | 1 (1.9) |
| Sarcomatoid features, n (%) | |
| Yes | 15 (28.8) |
| No | 37 (71.2) |
| Tumor PD-L1 expression, n (%) | n=39 |
| <1% | 24 (61.5) |
| ≥1% | 15 (38.5) |
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; PD-L1, programmed death ligand 1.